Medistep Healthcare SME IPO: GMP, Key Details & Expert Review (August 2025)
Medistep Healthcare IPO:
Grey Market Premium (GMP) & Latest Updates
As of August 8, 2025, the Grey Market Premium (GMP) for Medistep Healthcare IPO stands at ₹17 per share, indicating a strong market demand. Given the fixed IPO price of ₹43 per share, this GMP suggests an estimated listing price around ₹60, translating to a potential listing gain of approximately 39.5%.
Date IPO Price GMP Estimated Listing Price Estimated Listing Gain
08-Aug-25 ₹43 ₹17 ₹60 39.53%
07-Aug-25 ₹43 ₹17 ₹60 39.53%
06-Aug-25 ₹43 ₹12 ₹55 27.91%
Note: GMP values can fluctuate with market sentiment.
IPO Key Details
IPO Open Date: August 8, 2025
IPO Close Date: August 12, 2025
Issue Price: ₹43 per share (Fixed Price)
Face Value: ₹10 per share
Lot Size: 3,000 shares (Minimum investment for retail: 2 lots = 6,000 shares, approx. ₹2,58,000)
Issue Size: Approx ₹16.10 crore (Fresh issue of 37.44 lakh shares)
Listing Date: August 18, 2025
Listing Platform: NSE SME
Registrar: Cameo Corporate Services Limited
Business Overview
Medistep Healthcare Limited, incorporated in 2023 and based in Ahmedabad, Gujarat, operates in the healthcare and pharmaceutical sector. The company manufactures and trades pharmaceutical products, intimate care and hygiene products, surgical items, and nutraceuticals. It is noted for premium quality sanitary pads and energy powders, focusing on affordable and accessible healthcare solutions for community wellbeing. The company has also expanded by acquiring related businesses like M/s MG Pharma.
IPO Objectives
Fund working capital requirements
Prepayment or repayment of borrowings
Capital expenditure for business growth
General corporate purposes
Subscription & Market Sentiment
The IPO has attracted strong interest from retail investors, as reflected by the healthy GMP and fast subscription rates. The relatively high GMP indicates robust demand in the grey market, expected to yield attractive listing gains for investors who subscribe at the IPO price.
Analyst Review: Should You Invest?
Pros:
Strong growth potential in the healthcare and wellness sector
Diverse product portfolio including essential healthcare and hygiene items
Experienced promoters and management team
Attractive estimated listing gains based on current GMP
Cons:
High minimum investment size for retail investors due to large lot size
SME segment risks including liquidity and market volatility
Market fluctuations could impact final listing price and premium
Verdict: Medistep Healthcare IPO offers an exciting opportunity for medium- to long-term investors who want exposure to the growing healthcare and pharmaceutical industry. The promising GMP suggests good initial market reception, but investors should weigh risk factors inherent in SME IPOs before investing.
